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7RESEARCH Open AccessRegorafenib treatment for advanced, refractory
gastrointestinal stromal tumor: a report of the UK
managed access program
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Khin Thway2, Ellen McGrath2, Alison Dunlop2, Komel Khabra4, Beatrice Seddon3, Palma Dileo3, Mark Linch3,
Ian Judson2 and Charlotte Benson2Abstract
Background: Tyrosine kinase inhibitors (TKI) have revolutionized the treatment of gastrointestinal
stromal tumors (GIST) although most patients develop resistance to first and second-line therapies.
Regorafenib, an oral multi-targeted TKI, has demonstrated benefit in previously treated GIST patients.
Methods: We assessed safety and activity of regorafenib in patients treated within the Managed Access Program
(MAP). All consecutive patients with advanced GIST who had progressed on or were intolerant to imatinib and
sunitinib were recruited from the Royal Marsden and University College Hospitals. We retrospectively reviewed the
data for response, toxicity, treatment duration and survival. Response was assessed by RECIST and Choi criteria.
Toxicity was graded according to CTCAE v4.0 criteria.
Results: 20 patients were included in the MAP in the UK between 3/2013 and 9/2013. Median age was 68 (range
45–87), 65% of patients were male. Performance Status was 0–1 for 18 patients (90%), 2 for 2 patients (10%). The
median treatment duration was 9.25 months (range 0.1-15.33). 18 patients were assessable for response and all
patients attained a best response of at least stable disease. At a median follow-up of 12.6 months, there were 2
partial responses (11%) by RECIST and 7 partial responses (39%) according to Choi criteria. 7 patients remain on
regorafenib. 3 patients discontinued treatment due to unacceptable adverse events; fistulation, myalgia and fatigue.
10 (50%) patients had grade 3 toxicities and 11 (55%) patients required a dose reduction. Median PFS was
9.4 months (95% Cl: 6.2-not calculable) and median OS was 12.2 months (95% Cl: 10.5-not calculable). Notably,
prolonged stable disease was seen in 1 patient with exon 9 mutation and 1 patient with PDGFR D842V mutation.
Conclusions: These data demonstrate encouraging activity and tolerability of regorafenib in routine clinical
practice. The documented adverse events are in line with previous trial data.
Keywords: Gastrointestinal stromal tumor, Regorafenib, Mutation, ChoiBackground
Gastrointestinal stromal tumors (GIST) are the most com-
mon mesenchymal neoplasm in the gastrointestinal tract
with a worldwide incidence of approximately 15 cases per
million per year [1-3]. GIST are thought to be derived
from the interstitial cells of Cajal that coordinate the peri-
staltic action of the gastrointestinal tract [4]. In localized* Correspondence: attila.kollar@insel.ch
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unless otherwise stated.disease, the primary treatment modality is surgery but des-
pite complete resection, disease recurrence or metastasis
occurs in more than 40% of patients [3]. In this advanced
disease setting, cytotoxic chemotherapy has been largely
ineffective [5,6] however, molecular characterization of
GIST has transformed the therapeutic landscape [7]. The
majority of GIST have activating mutations in the genes
for stem cell factor receptor (KIT, 85%) or platelet derived
growth factor receptor α (PDGFRA, approximately 6-8%)
and more rarely exclusive mutations in BRAF, NF1 and
succinate dehydrogenase are found [2,8-12]. Introductiontd. This is an Open Access article distributed under the terms of the Creative
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PDGFRα has had a major impact in this disease and is
the standard 1st line therapy [13]. Sunitinib, a multiki-
nase inhibitor, is approved as second line therapy after
disease progression during imatinib or for patients that
are imatinib-intolerant [14].
Recently, regorafenib was introduced as a novel, oral
multikinase inhibitor whose effects are achieved by target-
ing angiogenic (VEGFR1–3 and TEK), stromal (PDGFR
and FGFR) and oncogenic (KIT, RET, RAF1, BRAF) recep-
tor tyrosine kinases [15-18]. Preclinical data has shown
that regorafenib has antitumor activity against human
GIST xenografts [19].
Following a phase I trial, which led to the recommended
dosing schedule of 160 mg OD 3 weeks on and 1 week off,
George and colleagues published the results of the multi-
centre phase II trial investigating the role of regorafenib in
metastatic and/or unresectable GIST with progression on
or intolerance to imatinib and prior failure of sunitinib.
12% (4/33) of the patients achieved a partial response (PR)
per RECIST 1.1. and 66% (22/33) experienced stable dis-
ease (SD) for longer than 16 weeks. Median progression-
free survival was 10.0 months [20,21].
Based on these promising results an international ran-
domized, double-blind, placebo-controlled phase III trial
(GRID) was conducted. 199 patients with metastatic or
unresectable GIST were randomized to receive 160 mg
of regorafenib or placebo, after failure of imatinib and
sunitinib. The median PFS was 4.8 months for regorafe-
nib vs 0.9 months for placebo. Overall survival at the
cutoff time was similar in both study arms, 22% events
in the regorafenib and 26% in the placebo group, re-
spectively. The median daily drug dose was 146.8 mg.
The two most commonly reported drug-related adverse
events were hand-foot-syndrome and hypertension [22].
Here we describe the safety and efficacy of regorafenib
in patients enrolled in a managed access program
(MAP), which was offered after the results of the GRID
trial have been published and before the commercial
launch. The MAP provided an opportunity to assess re-
gorafenib in a cohort of advanced GIST patients in a
routine clinical setting who had no other approved
therapeutic options.
Methods
Study design and population
The inclusion criteria were in the main in accordance with
the GRID trial [22]. In short, patients were eligible if they
were at least 18 years of age with histologically confirmed
metastatic and/or unresectable GIST, had progressed on
or were intolerant of imatinib and/or sunitinib, had a per-
formance status of 0–2 and had adequate haematological,
liver and renal function. Relevant exclusion criteria in-
cluded uncontrolled hypertension and any illness ormedical condition that was unstable or could jeopardize
the safety of the patient and his/her compliance in the
program.
We reviewed the data of all the consecutive patients re-
cruited into the MAP at the Royal Marsden and University
College London Hospitals. Patients’ data were prospectively
collected in the hospital electronic patient records systems.
Local institutional ethical approvals were obtained.
Treatment
All patients gave informed consent for treatment. Rego-
rafenib was started at the full dose of 160 mg orally once
daily for the first 3 weeks of each 4 week cycle. Initial
dose reductions were permitted depending on PS and/or
comorbidities according to the treating clinician’s discre-
tion. Patients were treated continuously until disease pro-
gression or unacceptable toxicities. Dose reductions were
implemented for moderate or severe toxicity. During the
MAP period, regorafenib was provided by Bayer plc.
Assessments
Tumor assessments were conducted with repeated com-
puter tomography (CT) scan and or magnetic resonance
imaging (MRI) at baseline and subsequently after every
2 cycles of treatment. Radiologic responses were assessed
according to RECIST 1.1 criteria [23] and Choi criteria
[24] by a single specialist Sarcoma Radiologist (C.M.).
Adverse events were monitored in all patients who re-
ceived regorafenib and graded according to the Common
Terminology Criteria for Adverse Events (CTCAE) version
4. All adverse events were recorded from the first intake
of regorafenib until treatment discontinuation.
Statistical analysis
Patient and disease characteristics were analysed using
descriptive statistics. Overall survival (OS) was defined
from date of starting treatment to date of death. Any
surviving patients were censored at last follow up. Pro-
gression free survival (PFS) was defined from date of
starting treatment to date of progression, assessed by
RECIST 1.1., or death. Any progression free surviving
patients were censored at last follow up. PFS and OS
were estimated using Kaplan-Meier analysis. Median fol-
low up was calculated using the inverse Kaplan Meier
method and the median rates and 6 month rates are pre-
sented along with the 95% Confidence Intervals (CI).
Results
Patient characteristics
Between March and September 2013, 20 consecutive pa-
tients with a diagnosis of metastatic GIST were included
in the MAP. Baseline characteristics are provided in
Table 1. Median age was 68 years (range 45–87). 13 (65%)
were male and 7 (35%) female. Most patients had an
Table 1 Patient characteristics
Total 20
Age (median, range) 68 (45-87)
n (%)
Sex
Male 13 (65%)
Female 7 (35%)
ECOG performance status at baseline
0-1 18 (90%)
2 2 (10%)
Site of primary
Gastric 8 (40%)
Non-gastric 12 (60%)
Previous treatment lines
2 16 (80%)
3 4 (20%)
Mutational analysis
KIT exon 11 mutation 12 (60%)
KIT exon 9 mutation 1 (5%)
PDGFR D842V mutation 1 (5%)
Not avalilable 6 (30%)
Table 2 Toxicity – number of patients/proportion out of
all 20 patients
Toxicity All grades Grade 3-4
Fatigue 16 (80%) 1 (5%)
Hand-foot-syndrome 11 (55%) 3 (15%)
Hypertension 10 (50%) 3 (15%)
Diarrhoea 10 (50%) -
Oral mucositis 8 (40%) 1 (5%)
Hoarseness 8 (40%) -
Constipation 7 (35%) -
Rash, maculopapular 6 (30%) 2 (10%)
Anorexia 5 (25%) -
Nausea 4 (20%) -
Hepatobiliary toxicity 2(10%) 1(5%)
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1, with 2 patients (10%) having a PS of 2. All the patients
had documented radiological progressive disease within
three months prior to starting on regorafenib. GIST was
of gastric origin in 8 (40%) patients. The remaining pa-
tients had GIST originating from small bowel, retroperi-
toneal, esophagogastric and one pelvic/rectal origin.
Mutational analysis was available for 14 patients, with a
majority of exon 11 mutations (60%); one patient had a
mutation in the exon 9 (5%) and another one had a
PDGFRA D842V mutation (5%). All the patients received
prior treatment with imatinib and sunitinib. Median time
on imatinib and sunitinib treatment was 37 months (range
2–87) and 11 months (range 2–46), respectively. Four pa-
tients (20%) received another line of treatment before re-
gorafenib was initiated; 3 of them in a phase I setting and
one patient received nilotinib. Median year of first diagno-
sis of GIST was 2006 (range 2000–2012). 5 patients re-
ceived post-study treatment; four with imatinib alone or
with a phase I investigational agent and one patient
radiotherapy.
Dosing and toxicity
The median treatment duration was 9.25 months (range
0.1-15.33). 15 (75%) patients started at the full dose of
160 mg. Starting dose was lower in 5 patients due to PS,
age and persisting toxicity from previous treatment; 3
patients started at 120 mg (15%) and 2 at 80 mg (10%)of regorafenib. 11 (55%) and 2 (10%) patients received dose
modification during the treatment, with dose reduction or
escalation, respectively. 3 patients (15%) discontinued treat-
ment during the first month of treatment. One patient ex-
perienced an exacerbation of a known fistula, one suffered
from severe pelvic pain and one from increasing fatigue. In
all patients, drug-related adverse events of any grade were
reported. The most common adverse events of any grade
were fatigue in 16 (80%) patients, hand-foot-skin reaction
in 11 (55%) patients and hypertension and diarrhea in half
of the patients. Laboratory abnormalities of any grade were
documented in 2 patients in terms of elevated alkaline
phosphatase and hyperbilirubinemia. Grade 3 toxicities
were documented in 10 patients (50%). 3 patients (15%)
each experienced hand-foot-skin reaction and hyperten-
sion, respectively, 2 (10%) patients reported skin rash, 1 pa-
tient (5%) had fatigue, one patient (5%) had oral mucositis
and in one patient a hyperbilirubinemia was reported. No
grade 4 toxicities or toxic deaths were reported. Toxicities
are summarized in Table 2.
Efficacy
After a median follow-up of 12.6 months, 18/20 patients
were assessable for response according to RECIST and
Choi criteria. Two patients were not assessable because
of early discontinuation before radiological assessment.
All assessable patients attained a best response of at least
stable disease. Two partial responses (11%) were docu-
mented according to RECIST. In comparison, assess-
ment by Choi criteria revealed a partial response in 7
patients (39%). An example of radiological response by
Choi is illustrated in Figure 1. Notably, in the 4 patients
that gained an improvement in PS, there was at least SD
by both RECIST (2 PR, 2 SD) and Choi (3 PR, 1 SD) cri-
teria. At the time of analysis (14.06.2014), 13 (65%) pa-
tients had discontinued regorafenib and 7 (35%) patients
were still benefiting from regorafenib treatment. The
Figure 1 Sagittal CT image of left upper quadrant mass.
Although the mass has increased in size, the drop in Hounsfield
units from 39 to 16 suggests partial response by Choi criteria.
Figure 3 Median OS: 12.2 months (95% CI: 10.5 – not calculable).
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and the 6-month PFS was 80.0% (95% CI 55.1-92.0)
(Figure 2). The median OS was 12.2 months (95% Cl:
10.5-not calculable) and the 6-month OS rate was
89.7% (95% CI 64.8-97.3) (Figure 3).
Discussion
Regorafenib is a multi-targeted tyrosine kinase inhibitor
with evidence of non-cross resistant activity in patients
with previously treated GIST. The phase III clinical trial
of regorafenib in GIST demonstrated a statistically sig-
nificant improved progression free survival in the third
line setting for patients with GIST following failure of
imatinib and sunitinib [22]. Its broad spectrum targeting
pathways involved in oncogenesis have made this drug
very appealing. In the MAP, patients with no other
therapeutic options had the opportunity to benefit from
regorafenib. We were able to assess efficacy and safety of
regorafenib treatment in a routine clinical practice set-
ting at two separate sarcoma centers in the UK.
Median treatment duration of regorafenib in the GRID
trial was reported to be 22.9 weeks which is approximatelyFigure 2 Median PFS: 9.4 months (95% CI: 6.2 – not calculable).3 months less than in our cohort. According to the
blinded central review and the investigator based assess-
ment median PFS in the phase III trial was 4.9 months
and 7.4 months, respectively, with a PFS at 6 months of
60%, also less than in our analysis. However these differ-
ences cannot be meaningfully compared due to our
smaller patient numbers and less rigorous inclusion and
stopping criteria. Interestingly a larger number of patients
received more than 2 previous treatment lines in the
GRID trial that could also account for such a difference.
Complete radiological responses were not seen in either
the GRID trial, or in the MAP. Twice as many partial re-
sponses were documented by RECIST criteria in our co-
hort in comparison with the trial setting, 11% and 4.5%,
respectively. Additionally, we assessed response according
to the Choi criteria taking into account the specific radio-
logical changes of GIST during TKI therapy. As expected,
the partial response rate according to Choi criteria was in-
creased compared with RECIST 1.1. Shinagare and col-
leagues reported recently on the correlation of different
assessment techniques with the outcome. Whereas PR was
more frequent by Choi (90%) than RECIST 1.1, disease
control rate was similar between the different tumor re-
sponse criteria. Interestingly, the concordance of RECIST
1.1 evaluation with PFS and OS was more exact than with
Choi [25]. Our data confirm that regorafenib has the po-
tential to control disease over many months. There were
not enough patients to make a fair comparison between
the two assessment criteria. However, the correlation be-
tween PS improvement and response was higher when
using response evaluation by Choi criteria.
Notably, we included one patient with an exon 9 and
one with a PDGFRA D842V mutation. Both patients ex-
perienced prolonged stable disease for 8 and 12 months,
respectively. A PR by Choi criteria was documented in
the PDGFRA mutated case. In five patients with primary
resistance to sunitinib, disease stabilization and even
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umented on regorafenib treatment suggesting non-cross
resistance of these agents. These findings support the
strategy that is currently being tested of alternating suni-
tinib and regorafenib in an attempt to try and overcome
acquired resistance mutations (NCT02164240).
All patients treated within the MAP experienced mild
adverse events. The documented toxicities, particularly of
grade 3, are consistent with previous published data. Fa-
tigue, hoarseness, constipation and rash were more often
reported in our cohort than in the GRID trial, but are simi-
lar to other published regorafenib studies [8,20,21,26-28].
The need to reduce the standard treatment dose of 160 mg
in more than half of the patients (55%) suggest that the op-
timal dose of regorafenib may be less than 160 mg. Patients
that received 120 mg once daily rarely suffered with ≥
grade 3 toxicities. The median daily dose of regorafenib in
the GRID trial was reported to be 146.8 mg in concordance
with our observation. Notably, our experience supports the
perception that the majority of adverse events are revers-
ible and manageable with dose delays, dose reductions and
intensified supportive care [29]. We performed clinical and
laboratory assessment of adverse events every two weeks
during the first 3 cycles. Specialist nursing input was avail-
able for patients receiving regorafenib, helping to raise pa-
tient awareness of expected side-effects and advise on
toxicity management in a timely fashion. We feel that these
intensive early assessments coupled with the nursing sup-
port plays a crucial part in successful management regoraf-
enib therapy.
Importantly for a trial of a palliative therapy, the GRID
study included quality of life outcomes, albeit only as ex-
ploratory endpoints. Poole and colleagues reported the
QoL data from assessments of global health status and
the physical functioning domain scores and demonstated
no statistical differences between the regorafenib and
placebo cohorts highlighting that regorafenib treatment
toxicities do not have a negative impact on QoL [30]. In
our study, formal QoL assessment was not performed
but PS was rigorously documented. Four out of 20 pa-
tients (20%) had improved their general status consistent
with the results seen in the GRID trial. This observation
that regorafenib is a well-tolerated treatment that leads
to symptomatic benefit in a sizeable proportion of pa-
tients in this study strengthens the role of regorafenib in
routine clinical practice. Furthermore, the fact that pa-
tients with a PS of 2 were included in the MAP and that
their adverse events were successfully managed makes
regorafenib treatment feasible in a real world population.
We feel that this toxicity management should include
close observation and consideration of a reduced initial
dose of regorafenib in patients who are PS 2 or who
have suffered with previous TKI toxicity. According to
the known phase III trials (CORRECT and GRID) thereseems to be no worsening of regorafenib toxicity follow-
ing treatment with other tyrosine kinase inhibitors like
imatinib or sunitinib [22,28].
Conclusions
In conclusion, our data confirms the efficacy and safety
data of the GRID trial supporting the use of regorafenib in
a real world setting including a range of differing muta-
tional subtypes. Additional data regarding the efficacy of
regorafenib in relation to the mutational status is needed.
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